JP6949952B2 - スピロ環化合物 - Google Patents
スピロ環化合物 Download PDFInfo
- Publication number
- JP6949952B2 JP6949952B2 JP2019518440A JP2019518440A JP6949952B2 JP 6949952 B2 JP6949952 B2 JP 6949952B2 JP 2019518440 A JP2019518440 A JP 2019518440A JP 2019518440 A JP2019518440 A JP 2019518440A JP 6949952 B2 JP6949952 B2 JP 6949952B2
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- salt
- compound
- compound according
- acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CC*(C([C@]1C*(CC(*(CC2)CC=C2c(cc2)ccc2C(OC(*C)=O)=*)=O)CC1)=O)c1cc(C(c(cc2N(C)CC)ccc2C#*)=*)c(*(C)C)cc1 Chemical compound CC*(C([C@]1C*(CC(*(CC2)CC=C2c(cc2)ccc2C(OC(*C)=O)=*)=O)CC1)=O)c1cc(C(c(cc2N(C)CC)ccc2C#*)=*)c(*(C)C)cc1 0.000 description 3
- KZDGDUSDTLBCJE-SSEXGKCCSA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2-c2n[n](C)cn2)=O)CC1)=O)c(cc1)cc2c1[nH]nc2-c(cc1)ccc1C#N Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2-c2n[n](C)cn2)=O)CC1)=O)c(cc1)cc2c1[nH]nc2-c(cc1)ccc1C#N KZDGDUSDTLBCJE-SSEXGKCCSA-N 0.000 description 1
- IWRIHOVBGLAUMI-MUUNZHRXSA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2-c2n[n](C)cn2)=O)CC1)=O)c(cc1)cc2c1[nH]nc2-c1ccc(C(F)(F)F)c(C#N)c1 Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2-c2n[n](C)cn2)=O)CC1)=O)c(cc1)cc2c1[nH]nc2-c1ccc(C(F)(F)F)c(C#N)c1 IWRIHOVBGLAUMI-MUUNZHRXSA-N 0.000 description 1
- KXGKLVDEBRIQFO-WJOKGBTCSA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2-c2n[n](C)cn2)=O)CC1)=O)c(cc12)ccc1[nH]nc2-c(cc1OC)ccc1C#[N]C Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2-c2n[n](C)cn2)=O)CC1)=O)c(cc12)ccc1[nH]nc2-c(cc1OC)ccc1C#[N]C KXGKLVDEBRIQFO-WJOKGBTCSA-N 0.000 description 1
- QLKKUCMECFGJPW-WJOKGBTCSA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)cc(C(c(cc2)ccc2OC(C)C)=N)c1N Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)cc(C(c(cc2)ccc2OC(C)C)=N)c1N QLKKUCMECFGJPW-WJOKGBTCSA-N 0.000 description 1
- HFJWYIRBCXJXCP-GDLZYMKVSA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)cc2c1[nH]nc2-c(cc1C#N)ccc1OC Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)cc2c1[nH]nc2-c(cc1C#N)ccc1OC HFJWYIRBCXJXCP-GDLZYMKVSA-N 0.000 description 1
- NZGODKRGDVEIHO-MUUNZHRXSA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)nc(C(N2CCC3(COC3)CC2)=N)c1N Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)nc(C(N2CCC3(COC3)CC2)=N)c1N NZGODKRGDVEIHO-MUUNZHRXSA-N 0.000 description 1
- UGQWPDPHUJLHHG-SSEXGKCCSA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)nc(C(c(cc2)ccc2OC(C)C)=N)c1N Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)nc(C(c(cc2)ccc2OC(C)C)=N)c1N UGQWPDPHUJLHHG-SSEXGKCCSA-N 0.000 description 1
- JCMIVDUCQQWBKF-SSEXGKCCSA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)nc(C(c(cc2OC)ccc2OC(C)C)=N)c1N Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)nc(C(c(cc2OC)ccc2OC(C)C)=N)c1N JCMIVDUCQQWBKF-SSEXGKCCSA-N 0.000 description 1
- WKBRCYUPJGVUHK-GDLZYMKVSA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(O2)=NN(C)C2=O)=O)CC1)=O)c(cc1)cc2c1[nH]nc2-c(cc1)ccc1C#N Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(O2)=NN(C)C2=O)=O)CC1)=O)c(cc1)cc2c1[nH]nc2-c(cc1)ccc1C#N WKBRCYUPJGVUHK-GDLZYMKVSA-N 0.000 description 1
- YHTVCPYYJHUOHR-GDLZYMKVSA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(O2)=NN(C)C2=O)=O)CC1)=O)c(cc1)cc2c1[nH]nc2-c(cc1)cnc1OC(C)C Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(O2)=NN(C)C2=O)=O)CC1)=O)c(cc1)cc2c1[nH]nc2-c(cc1)cnc1OC(C)C YHTVCPYYJHUOHR-GDLZYMKVSA-N 0.000 description 1
- NDYZERRPOSDION-GDLZYMKVSA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(O2)=NN(C)C2=O)=O)CC1)=O)c(cc1)cc2c1[nH]nc2-c1cccc(C#N)c1 Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(O2)=NN(C)C2=O)=O)CC1)=O)c(cc1)cc2c1[nH]nc2-c1cccc(C#N)c1 NDYZERRPOSDION-GDLZYMKVSA-N 0.000 description 1
- JKQXUYKLHYCEJL-MUUNZHRXSA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(O2)=NN(C)C2=O)=O)CC1)=O)c(cc12)ccc1[nH]nc2-c(cc1C#N)ccc1OC Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(O2)=NN(C)C2=O)=O)CC1)=O)c(cc12)ccc1[nH]nc2-c(cc1C#N)ccc1OC JKQXUYKLHYCEJL-MUUNZHRXSA-N 0.000 description 1
- NNJLNLUKNJWBQJ-SSEXGKCCSA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(O2)=NN(C)C2=O)=O)CC1)=O)c(cc12)ccc1[nH]nc2-c(cc1OC)ccc1C#[N]C Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(O2)=NN(C)C2=O)=O)CC1)=O)c(cc12)ccc1[nH]nc2-c(cc1OC)ccc1C#[N]C NNJLNLUKNJWBQJ-SSEXGKCCSA-N 0.000 description 1
- PXLRXJWIKHLWRW-AREMUKBSSA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c2ncc(-c3n[n](C)cn3)[s]2)=O)CC1)=O)c(cc1)cc(C(c(cc2)ccc2OC(C)C)=N)c1N Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c2ncc(-c3n[n](C)cn3)[s]2)=O)CC1)=O)c(cc1)cc(C(c(cc2)ccc2OC(C)C)=N)c1N PXLRXJWIKHLWRW-AREMUKBSSA-N 0.000 description 1
- AJMAZXQDNAHQJZ-AREMUKBSSA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c2ncc(/C(/N=C\NC)=N/C)[s]2)=O)CC1)=O)c(cc1)nc(C(c(cc2OC)ccc2OC(C)C)=N)c1N Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c2ncc(/C(/N=C\NC)=N/C)[s]2)=O)CC1)=O)c(cc1)nc(C(c(cc2OC)ccc2OC(C)C)=N)c1N AJMAZXQDNAHQJZ-AREMUKBSSA-N 0.000 description 1
- VGWBWSNFRKSYAS-UHFFFAOYSA-N C[n]1nc(-c2ccc(C(CC3)CCN3C(CCl)=O)cc2)nc1 Chemical compound C[n]1nc(-c2ccc(C(CC3)CCN3C(CCl)=O)cc2)nc1 VGWBWSNFRKSYAS-UHFFFAOYSA-N 0.000 description 1
- ONIFNICATWBCHW-UHFFFAOYSA-N Cc1n[n](C)cn1 Chemical compound Cc1n[n](C)cn1 ONIFNICATWBCHW-UHFFFAOYSA-N 0.000 description 1
- KGSDBFAYJUPWSS-UHFFFAOYSA-N O=C(c1ccccc1)ON(CC1)CC1(CCN1)C1=O Chemical compound O=C(c1ccccc1)ON(CC1)CC1(CCN1)C1=O KGSDBFAYJUPWSS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021154677A JP2021193138A (ja) | 2016-10-05 | 2021-09-22 | スピロ環化合物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662404668P | 2016-10-05 | 2016-10-05 | |
| US62/404,668 | 2016-10-05 | ||
| PCT/US2017/054865 WO2018067512A1 (en) | 2016-10-05 | 2017-10-03 | Spirocyclic compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021154677A Division JP2021193138A (ja) | 2016-10-05 | 2021-09-22 | スピロ環化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019534261A JP2019534261A (ja) | 2019-11-28 |
| JP2019534261A5 JP2019534261A5 (enExample) | 2020-11-12 |
| JP6949952B2 true JP6949952B2 (ja) | 2021-10-13 |
Family
ID=61831517
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019518440A Expired - Fee Related JP6949952B2 (ja) | 2016-10-05 | 2017-10-03 | スピロ環化合物 |
| JP2021154677A Pending JP2021193138A (ja) | 2016-10-05 | 2021-09-22 | スピロ環化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021154677A Pending JP2021193138A (ja) | 2016-10-05 | 2021-09-22 | スピロ環化合物 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10934304B2 (enExample) |
| EP (1) | EP3523306A4 (enExample) |
| JP (2) | JP6949952B2 (enExample) |
| KR (1) | KR20190075931A (enExample) |
| CN (1) | CN109890827A (enExample) |
| AU (1) | AU2017339890A1 (enExample) |
| BR (1) | BR112019005305A2 (enExample) |
| CA (1) | CA3037064A1 (enExample) |
| IL (1) | IL265752A (enExample) |
| MX (1) | MX2019003938A (enExample) |
| RU (1) | RU2019107667A (enExample) |
| TW (1) | TW201817732A (enExample) |
| WO (1) | WO2018067512A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2876689C (en) | 2012-06-13 | 2022-04-26 | Incyte Corporation | Substituted tricyclic compounds as fgfr inhibitors |
| PH12015502383B1 (en) | 2013-04-19 | 2023-02-03 | Incyte Holdings Corp | Bicyclic heterocycles as fgfr inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| CA2976790C (en) | 2015-02-20 | 2024-02-27 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| EP3277690B1 (en) | 2015-04-03 | 2020-02-26 | Recurium IP Holdings, LLC | Spirocyclic compounds |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| RS66310B1 (sr) | 2018-05-04 | 2025-01-31 | Incyte Corp | Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu |
| KR102956194B1 (ko) | 2018-05-04 | 2026-04-23 | 인사이트 코포레이션 | Fgfr 억제제의 염 |
| AU2019334264B2 (en) * | 2018-09-07 | 2024-10-31 | Merck Patent Gmbh | 5-Morpholin-4-yl-pyrazolo[4,3-b]pyridine derivatives |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| WO2021007269A1 (en) * | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| US12122767B2 (en) | 2019-10-01 | 2024-10-22 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| GEP20247679B (en) | 2019-10-14 | 2024-10-10 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021113479A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| MX2022006691A (es) | 2019-12-04 | 2022-09-19 | Incyte Corp | Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr). |
| CN110922421B (zh) * | 2019-12-17 | 2023-05-05 | 安徽英特美科技有限公司 | 一种n-甲基-1,2,5,6-四氢吡啶-4-硼酸频哪醇酯的合成方法 |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| EP4323405A1 (en) | 2021-04-12 | 2024-02-21 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| CA3220274A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| TW202313610A (zh) | 2021-06-09 | 2023-04-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之三環雜環 |
| CN122094959A (zh) * | 2023-10-31 | 2026-05-26 | C4医药公司 | 用于降解突变体braf的化合物 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2897422T3 (es) * | 2004-05-14 | 2022-03-01 | Vertex Pharma | Compuestos pirroles como inhibidores de proteínas cinasas ERK y composiciones farmacéuticas que contienen esos compuestos |
| ES2372976T3 (es) * | 2005-12-13 | 2012-01-30 | Schering Corporation | Derivados de indazol policíclicos que son inhibidores de erk. |
| JP5380296B2 (ja) | 2006-11-17 | 2014-01-08 | ポリエラ コーポレイション | ジイミド系半導体材料ならびにジイミド系半導体材料を調製および使用する方法 |
| MX2009014208A (es) * | 2007-06-18 | 2010-01-28 | Schering Corp | Compuestos heterociclicos y usos de los mismos como inhibidores de erk. |
| EP2318388A2 (en) | 2008-07-23 | 2011-05-11 | Schering Corporation | Tricyclic spirocycle derivatives and methods of use thereof |
| CA3044884A1 (en) | 2009-12-07 | 2011-06-16 | Arbutus Biopharma Corporation | Compositions for nucleic acid delivery |
| WO2013033059A1 (en) * | 2011-08-29 | 2013-03-07 | Bristol-Myers Squibb Company | Spiro bicyclic diamine derivatives as hiv attachment inhibitors |
| CN103130775B (zh) | 2011-11-22 | 2015-09-30 | 山东亨利医药科技有限责任公司 | 作为酪氨酸激酶抑制剂的吲哚满酮衍生物 |
| US8987264B2 (en) * | 2012-11-09 | 2015-03-24 | Bristol-Myers Squibb Company | 1,3,5-triazine derivatives of spiro bicyclic oxalamide-compounds for treatment of hepatitis C |
| US9447025B2 (en) | 2013-03-14 | 2016-09-20 | Kalyra Pharmaceuticals, Inc. | Bicyclic analgesic compounds |
| JP6322770B2 (ja) | 2014-12-22 | 2018-05-09 | イーライ リリー アンド カンパニー | Ｅｒｋ阻害剤 |
| CN105732636B (zh) | 2014-12-30 | 2020-04-21 | 广东东阳光药业有限公司 | 杂芳化合物及其在药物中的应用 |
| EP3277690B1 (en) * | 2015-04-03 | 2020-02-26 | Recurium IP Holdings, LLC | Spirocyclic compounds |
-
2017
- 2017-10-03 KR KR1020197012021A patent/KR20190075931A/ko not_active Ceased
- 2017-10-03 JP JP2019518440A patent/JP6949952B2/ja not_active Expired - Fee Related
- 2017-10-03 AU AU2017339890A patent/AU2017339890A1/en not_active Abandoned
- 2017-10-03 CN CN201780067175.6A patent/CN109890827A/zh active Pending
- 2017-10-03 WO PCT/US2017/054865 patent/WO2018067512A1/en not_active Ceased
- 2017-10-03 BR BR112019005305A patent/BR112019005305A2/pt not_active Application Discontinuation
- 2017-10-03 US US16/336,854 patent/US10934304B2/en not_active Expired - Fee Related
- 2017-10-03 MX MX2019003938A patent/MX2019003938A/es unknown
- 2017-10-03 CA CA3037064A patent/CA3037064A1/en not_active Abandoned
- 2017-10-03 EP EP17858989.1A patent/EP3523306A4/en not_active Withdrawn
- 2017-10-03 RU RU2019107667A patent/RU2019107667A/ru not_active Application Discontinuation
- 2017-10-05 TW TW106134299A patent/TW201817732A/zh unknown
-
2019
- 2019-04-01 IL IL265752A patent/IL265752A/en unknown
-
2020
- 2020-12-18 US US17/127,710 patent/US20210115058A1/en not_active Abandoned
-
2021
- 2021-09-22 JP JP2021154677A patent/JP2021193138A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20210115058A1 (en) | 2021-04-22 |
| MX2019003938A (es) | 2019-06-10 |
| AU2017339890A1 (en) | 2019-04-11 |
| US20200207776A1 (en) | 2020-07-02 |
| TW201817732A (zh) | 2018-05-16 |
| CN109890827A (zh) | 2019-06-14 |
| RU2019107667A (ru) | 2020-11-06 |
| RU2019107667A3 (enExample) | 2021-01-27 |
| EP3523306A1 (en) | 2019-08-14 |
| KR20190075931A (ko) | 2019-07-01 |
| JP2021193138A (ja) | 2021-12-23 |
| WO2018067512A8 (en) | 2018-11-01 |
| WO2018067512A1 (en) | 2018-04-12 |
| EP3523306A4 (en) | 2020-05-06 |
| US10934304B2 (en) | 2021-03-02 |
| JP2019534261A (ja) | 2019-11-28 |
| BR112019005305A2 (pt) | 2019-07-02 |
| NZ751398A (en) | 2021-03-26 |
| IL265752A (en) | 2019-06-30 |
| CA3037064A1 (en) | 2018-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021193138A (ja) | スピロ環化合物 | |
| US12264147B2 (en) | Substituted carboxamides as inhibitors of WDR5 protein-protein binding | |
| US10493060B2 (en) | Spirocyclic compounds | |
| US20260138983A1 (en) | FGFR Inhibitors and Methods of Use Thereof | |
| JP2018158942A (ja) | Ｔａｎｋ結合キナーゼ阻害剤化合物として有用なアミノトリアジン誘導体 | |
| US20190071416A1 (en) | Compounds for treatment of cancer and epigenetics | |
| KR20210153051A (ko) | 매크로사이클릭 화합물 | |
| NZ751398B2 (en) | Spirocyclic compounds | |
| TW202126639A (zh) | 吡咯啶基系化合物 | |
| HK1256671B (en) | Spirocyclic compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A529 | Written submission of copy of amendment under article 34 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A529 Effective date: 20190605 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200930 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200930 |
|
| TRDD | Decision of grant or rejection written | ||
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210819 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210824 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210922 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6949952 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |